Fig. 3 | Nature Communications

Fig. 3

From: Survival of pancreatic cancer cells lacking KRAS function

Fig. 3

KRAS deficient cells are dependent on PI3K. a Heat map of area under the curve (AUC) for KRAS intact and deficient (KO) clones (columns) treated with various compounds. Row normalized data are presented with red designating high AUC (less sensitive) and blue denoting low AUC (more sensitive). Shown are hit compounds (see “Methods” section) exhibiting greater sensitivity in KRAS deficient cells listed in order of ΔAUC from highest to lowest. PI3K and mTOR inhibitors are noted. See Supplementary Data 4 for full data set. b Dose-response curves of 8988T KRAS intact (gray) and deficient (purple) cells to the pan-PI3K inhibitors GDC-0941 and BAY80-6946. Each replicate (n = 3 for each dose) and curve fit are shown. c Increased apoptosis (change in percentage Annexin V-positive cells vs. DMSO) in KRAS deficient (KO) cells 48 h after 2 μM GDC-0941 treatment. Average ± s.e.m. is plotted (n = 2 clones per group). *p < 0.05, two-tailed Student’s t test. d Dose-response curves of A13 cells to pan-PI3K inhibitors. Each replicate (n = 3 for each dose) and curve fit are shown. e GDC-0941 significantly decreased the growth rate of KRAS deficient (KO) but not intact A13 transplanted tumors in nude mice. Average tumor volume fold increase (normalized to start of treatment at day 0) ± s.e.m. (n = 8 tumors per group) is plotted. *p < 0.05, **p < 0.01, two-tailed Student’s t test for measurements at each time point comparing GDC-0941 to vehicle